Leading Pharmaceutical Company, Glenmark has launched antiviral drug Favipiravir, under the brand name FabiFlu which it claims help the treatment of patients with mild to moderate COVID-19. The Mumbai-based company got manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19 and the company claims that it help ease the pressure on the healthcare system when cases in India are spiraling like never before. It has shown encouraging response in mild to moderate COVID-19 patients during clinical trials.
The drug will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1,800 mg twice on day one, followed by 800 mg twice daily up to day 14. It will still make it a costly drug. Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections.
According to the medical bulletin released by the Union Ministry of Health and Family Welfare, India recorded the Highest single-day spike of 14,516 COVID-19 cases yesterday pushing the country’s tally to 3,95,048; death toll rises to 12,948 with 375 new fatalities
